Modality
ERT
MOA
BiTE
Target
KIF18A
Pathway
PD-1/PD-L1
Bladder Ca
Development Pipeline
Preclinical
Jun 2018
→ Jun 2031
PreclinicalCurrent
NCT03554100
273 pts·Bladder Ca
2018-06→2031-06·Active
273 total pts1 indication
Phase 1
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2031-06-095.2y awayInterim· Bladder Ca
Trial Timeline
Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2Q3
Preclinical
Active
Catalysts
Interim
2031-06-09 · 5.2y away
Bladder Ca
Active|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03554100 | Preclinical | Bladder Ca | Active | 273 | CR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Niranesiran | Johnson & Johnson | Phase 2 | KIF18A | |
| LLY-3251 | Eli Lilly | Phase 2 | MDM2 | |
| Zanutinib | Bristol-Myers Squibb | Phase 2/3 | APOC3 | |
| Bemarelsin | Daiichi Sankyo | Preclinical | GLP-1R | |
| DSN-7360 | Daiichi Sankyo | Approved | SGLT2 | |
| Riluinavolisib | Moderna | NDA/BLA | KIF18A | |
| BII-8315 | Biogen | NDA/BLA | CDK2 | |
| Geliglumide | Samsung Biologics | Phase 1 | Aβ | |
| NUV-2032 | Nuvalent | Preclinical | KIF18A | |
| AXS-4984 | Axsome | Preclinical | JAK2 |